DCGI sees Merck drug less effective against moderate Covid: Report

Must read

Milagrow iMap Max, iMap 10.0, Seagull Robot Vacuum Cleaners Launched in India

Milagrow, an Indian consumer robots brand, has launched three new floor robot vacuums in the country. The cleaning devices will go on sale...

Leaked Pixel 6 and 6 Pro ads include ‘Magic Eraser’ demo

Following high-resolution images today, promo ads for the Pixel 6 and Pixel 6 Pro have leaked this evening. These 30-second videos show off...

How to cast and screen mirror from your phone to a Roku device

Source: Keegan Prosser/ Android Central Roku devices give users the ability to stream content from hundreds of apps, but there are a handful of...
Bhawani Singhhttps://techmepro.com
I am a blogger who believes in delivering latest tech news from around the world to my viewers.

Merck & Co’s experimental antiviral drug molnupiravir has not shown “significant efficacy” against moderate Covid-19, Reuters reported quoting a source with the Drug Controller General of India (DCGI).

Aurobindo Pharma Ltd wants to discontinue a late-stage trial of molnupiravir in moderate Covid-19 patients, the regulator’s expert committee said on Friday.

“There is no significant efficacy against moderate Covid and the effective efficacy is towards mild cases,” the source said on condition of anonymity due to the sensitive nature of the discussions.

The regulator and health ministry did not immediately respond to a request seeking comment.

In an interim analysis of a late-stage clinical trial, molnupiravir is said to have reduced the risk of hospitalisation or death by 50%, Merck and partner Ridgeback Biotherapeutics LP announced earlier.

Merck earlier this year announced that it had signed non-exclusive voluntary licensing agreements for the drug with five generic manufacturers in India in a bid to accelerate availability in more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies.

The American pharma firm has said it will seek an emergency-use authorisation from the FDA of the drug molnupiravir.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint.
our App Now!!

Source link